Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis

Aberrant expression or hyperactivation of aromatase (CYP19A1)–estrogen receptor (ESR) axis is well identified as one of the major causes of breast cancer. Lots of drugs have been developed for targeting CYP19A1 or ESR respectively, such as anastrozole and fulvestrant. Recently, Mehta et al. reported...

Descripción completa

Detalles Bibliográficos
Autor principal: Huang, Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861394/
https://www.ncbi.nlm.nih.gov/pubmed/31741086
http://dx.doi.org/10.1186/s40169-019-0246-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861394/
https://www.ncbi.nlm.nih.gov/pubmed/31741086
http://dx.doi.org/10.1186/s40169-019-0246-5

Ejemplares similares